Ц.Билэгтсайхан
Loading...
Товч нэр
Ц.Билэгтсайхан
Бүтэн нэр
Цолмон Билэгтсайхан
Латин нэр
Tsolmon Bilegtsaikhan
Албан тушаал
Проректор
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
12 results
Now showing 1 - 10 of 12
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019-2022)(2025-11) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D ;Batsaikhan, PurevsurenSuuri, BujinlkhamBACKGROUND: Streptococcus pneumoniae is an important cause of pneumonia in older adults, however, serotyping and indirect impact information from low and middle-income countries is lacking. Mongolia has a childhood 13-valent pneumococcal conjugate vaccine (PCV13) program, but no adult pneumococcal vaccination program. We describe pneumococcal carriage rates, disease and serotype distribution among adults hospitalised with pneumonia, and explore changes over the COVID-19 pandemic period. METHODS: Adults (≥ 18 years) hospitalised with clinical pneumonia were enrolled over 3 years (March 2019-February 2022) into a prospective pneumonia surveillance program. Nasopharyngeal swabs were tested to detect pneumococci using lytA qPCR and molecular serotyping by DNA microarray and metagenomics. Pneumococcal pneumonia was identified using serotype-specific urinary antigen detection and BinaxNOW® assays. Pneumococcal carriage and pneumonia prevalence were assessed over the COVID-19 period with log-binomial regression used to estimate prevalence and adjusted prevalence ratios (pre- versus early- and late-COVID-19 periods). RESULTS: Of 3,178 pneumonia cases, S. pneumoniae was identified in 12.1% (333/2,759) of swabs and 8.6% (253/2,925) of urine samples. PCV13 serotype carriage prevalence was 3.1% (82/2,663) and non-PCV13 serotype carriage prevalence 5.7% (152/2,663). In the late-COVID-19 period, pneumococcal carriage prevalence was reduced by 66% (aPR 0.34, 95%CI 0.25-0.46) and pneumococcal pneumonia by 82% (aPR 0.18, 95%CI 0.12-0.27) compared with the pre-COVID-19 transmission period. CONCLUSION: Despite paediatric vaccination with high coverage, we identified some residual PCV13 serotypes with predominance of non-PCV13 serotypes carried and causing disease in adults. Direct adult vaccination which targets these serotypes will potentially reduce disease in adults in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial(Elsevier BV, 2025-11) ;Batmunkh, Tsetsegsaikhan ;Neal, Eleanor F G ;Amraa, Otgonjargal ;Mazarakis, NadiaAltangerel, BolorBACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Respiratory Syncytial Virus and Influenza Infections in Children in Ulaanbaatar, Mongolia, 2015-2021(2024-05) ;Do, Lien Anh Ha ;Tsedenbal, Naranzul ;Khishigmunkh, Chimidregzen ;Tserendulam, BazarkhuuAltanbumba, LkhagvadorjBACKGROUND: Data available for RSV and influenza infections among children < 2 years in Mongolia are limited. We present data from four districts of Ulaanbaatar from April 2015 to June 2021. METHODS: This study was nested in an enhanced surveillance project evaluating pneumococcal conjugate vaccine (PCV13) impact on the incidence of hospitalized lower respiratory tract infections (LRTIs). Our study was restricted to children aged < 2 years with arterial O2 saturation < 93% and children with radiological pneumonia. Nasopharyngeal (NP) swabs collected at admission were tested for RSV and influenza using qRT-PCR. NP swabs of all patients with radiological pneumonia and of a subset of randomly selected NP swabs were tested for S. pneumoniae (S.p.) by qPCR and for serotypes by culture and DNA microarray. RESULTS: Among 5705 patients, 2113 (37.0%) and 386 (6.8%) had RSV and influenza infections, respectively. Children aged 2-6 months had a higher percentage of very severe RSV infection compared to those older than 6 months (42.2% versus 31.4%, p-value Fisher's exact = 0.001). S.p. carriage was detected in 1073/2281 (47.0%) patients. Among S.p. carriage cases, 363/1073 (33.8%) had S.p. and RSV codetection, and 82/1073 (7.6%) had S.p. and influenza codetection. S.p. codetection with RSV/influenza was not associated with more severe LRTIs, compared to only RSV/influenza cases. CONCLUSION: In Mongolia, RSV is an important pathogen causing more severe LRTI in children under 6 months of age. Codetection of RSV or influenza virus and S.p. was not associated with increased severity.Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia hospitalisations in Mongolia: a time series analysis(2024-03) ;Fagerli, Kirsten ;Ulziibayar, Munkhchuluun ;Suuri, Bujinlkham ;Luvsantseren, DashtserenNarangerel, DorjBACKGROUND: Few studies have assessed the potential indirect effects of childhood pneumococcal conjugate vaccine (PCV) programs on the adult pneumonia burden in resource-limited settings. We evaluated the impact of childhood PCV13 immunisation on adult all-cause pneumonia following a phased program introduction from 2016. METHODS: We conducted a time-series analysis to assess changes in pneumonia hospitalisation incidence at four district hospitals in Mongolia. Adults (≥18 years) that met the clinical case definition for all-cause pneumonia were enrolled. A negative binomial mixed-effects model was used to assess the impact of PCV13 introduction on monthly counts of pneumonia admissions from January 2015-February 2022. We also performed a restricted analysis excluding the COVID-19 pandemic period. All models were stratified by age and assessed separately. Additional analyses assessed the robustness of our findings. FINDINGS: The average annual incidence of all-cause pneumonia hospitalisation was highest in adults 65+ years (62.81 per 10,000 population) and declined with decreasing age. After adjusting for the COVID-19 pandemic period, we found that rates of pneumonia hospitalisation remained largely unchanged over time. We did not observe a reduction in pneumonia hospitalisation in any age group. Results from restricted and sensitivity analyses were comparable to the primary results, finding limited evidence of a reduced pneumonia burden. INTERPRETATION: We did not find evidence of indirect protection against all-cause pneumonia in adults following childhood PCV13 introduction. Direct pneumococcal vaccination and other interventions should be considered to reduce burden of pneumonia among older adults. FUNDING: Pfizer clinical research collaboration agreement (contract number: WI236621).Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial(Elsevier BV, 2024-01) ;Batmunkh, Tsetsegsaikhan ;Moore, Kerryn A ;Thomson, Helen ;Altangerel, BolorAmraa, OtgonjargalBACKGROUND: COVID-19 vaccine booster doses restore vaccine effectiveness lost from waning immunity and emerging variants. Fractional dosing may improve COVID-19 booster acceptability and uptake and will reduce the per-dose cost of COVID-19 booster programmes. We sought to quantify the immunogenicity, reactogenicity, and safety of a half-dose BNT162b2 (Pfizer-BioNTech) booster relative to the standard formulation. METHODS: This randomised, controlled, non-inferiority trial recruited adults in Mongolia primed with a two-dose homologous ChAdOx1 nCov-19 (Oxford-AstraZeneca, n = 129 participants), BBIBP-CorV (Sinopharm (Beijing), n = 399), or Gam-COVID-Vac (Gamaleya, n = 70) schedule. Participants were randomised (1:1) to receive a 15 μg (half-dose) or 30 μg (full-dose) BNT162b2 booster. Participants and study staff assessing reactogenicity were blinded up to day 28. Co-primary endpoints were Wuhan-Hu-1 anti-spike S1 IgG seroresponse 28 days post-boosting and reactogenicity within 7 days of boosting. The non-inferiority margin for the absolute difference in seroresponse was -10%. Differences in seroresponse were estimated from logistic regression with marginal standardisation. Geometric mean ratios of IgG were also estimated. ClinicalTrials.gov Identifier: NCT05265065. FINDINGS: Between May 27th and September 30th, 2022, 601 participants were randomized to full-dose BNT162b2 (n = 300) or half-dose (n = 301). 598 were included in safety analyses, and 587 in immunological analyses. The frequency of grade 3-4 reactions was similar between arms (half-dose: 4/299 [1.3%]; full-dose: 6/299 [2.0%]). Across all severity grades, half-dose recipients reported fewer local and systemic reactions (60% versus 72% and 25% versus 32%, respectively). Seroresponse was 84.7% (250/295) and 86.6% (253/292) in the half-dose and full-dose arms, respectively (Difference: -2.8%; 95% CI -7.7, 2.1). Geometric mean IgG titres were similar in those receiving full and half-dose boosters for the ChAdOx1 and BBIBP-CorV primed groups, but lower in the half-dose arm in Gam-COVID-Vac-primed participants (GMR: 0.71; 95% CI 0.54, 0.93). INTERPRETATION: Half-dose BNT162b2 boosting elicited an immune response that was non-inferior to a full-dose, with fewer reactions, in adults primed with ChAdOx1 nCov-19 or BBIBP-CorV. Half-dose boosting may not be suitable in adults primed with Gam-COVID-Vac. Half-dose BNT162b2 boosting may be considered in populations primed with ChAdOx1 nCov-19 or BBIBP-CorV. FUNDING: Coalition for Epidemic Preparedness Innovations (CEPI).Scopus© Citations 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia(2026-01) ;Simkiss, Amy ;Ulziibayar, Munkhchuluun ;Batsaikhan, Purevsuren ;Suuri, BujinlkhamLuvsantseren, DashtserenBACKGROUND: Limited research has focused on risk factors for community acquired pneumonia (CAP) in adults in low-middle income countries (LMICs). Mongolia has high rates of CAP hospitalisations with extreme winter temperatures and significant air pollution. We aimed to examine risk factors for severe CAP among hospitalised adults aged ≥ 18 years in Mongolia. METHODS: Adults hospitalised with clinical CAP were enrolled over three years (2019–2022) into a prospective CAP surveillance program in four district hospitals in the capital city, Ulaanbaatar. Participants had clinical information and risk factors collected using a case report form. Nasopharyngeal swabs were collected and tested for Streptococcus pneumoniae (the pneumococcus), influenza and respiratory syncytial virus, while collected urine was tested for the pneumococcus. From 2020 only patients with a negative SARS-CoV-2 test were enrolled in the study. Severe CAP was defined as clinical CAP with intensive care unit admission or ≥ 2 severity signs (confusion, hypotension, tachypnoea or hypoxaemia). Multivariable logistic regression was used to derive adjusted risk factor estimates. RESULTS: Overall, 3178 participants met the CAP study case definition and 10.1% had severe CAP. Pneumococcal carriage (aOR:2.67; 95% CI:1.88–3.79; p < 0.001), pneumococcal serotype-specific urine antigen detection positivity (aOR:1.69; 95% CI:1.11–2.57; p = 0.01), hospital admission within the last year (aOR:1.73; 95% CI:1.26–2.37; p = 0.001), underlying medical conditions (aOR:1.96; 95% CI:1.39–2.76; p < 0.001), cigarette smoking (aOR:1.53; 95% CI:1.08–2.16; p = 0.01) and alcohol intake (aOR:2.19; 95% CI:1.49–3.22; p < 0.001), were identified as risk factors for severe CAP on multivariable analysis. CONCLUSION: We identified key risk factors for severe CAP in hospitalised adults in urban Mongolia. If resources are limited, this data could be used to prioritise groups for vaccinations, alongside public health policies to decrease tobacco smoking and alcohol consumption.Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial(2026) ;Batmunkh, Tsetsegsaikhan ;Neal, Eleanor Fg ;Amraa, Otgonjargal ;Mazarakis, NadiaAltangerel, BolorINTRODUCTION: COVID-19 boosters restore waning immunity. After demonstrating non-inferiority of 15 μg versus 30 μg BNT162b2 at 28 days in Mongolian adults, we assessed 24-month immunogenicity and safety. METHODS: In this randomised, controlled trial, adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were assigned (1:1) to 15 μg or 30 μg BNT162b2. Anti-spike IgG, surrogate virus neutralisation (sVNT) against Wuhan-Hu-1 and Omicron BA.1, and interferon-gamma (IFN-γ) release assays (Ag1/Ag2) were assessed to 24 months. SARS-CoV-2 infections and serious adverse events (SAEs) were recorded. ClinicalTrials.gov: NCT05265065. RESULTS: Of 601 participants, 520 (86.5%) completed follow-up. IgG and IFN-γ responses were comparable between arms at 24 months (IgG geometric mean ratio (GMR) 1.06 [95% CI 0.95-1.18]; Ag1 GMR 1.17 [95% CI 0.82-1.66]; Ag2 GMR 1.06 [95% CI 0.73-1.54]). Median sVNT inhibition remained high (Wuhan-Hu-1 88% [interquartile range (IQR) 86-90]; Omicron BA.1 85% [IQR 70-88]). Twenty-eight SARS-CoV-2 infections occurred. Fifty-three SAEs were balanced by study arm, and none were vaccine related. DISCUSSION: Equivalent immunity and safety from 15 μg and 30 μg BNT162b2 boosters support fractional dosing as a cost-saving strategy. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05265065, identifier NCT05265065.Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia(2024-08) ;von Mollendorf, Claire ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Skoko, PaigeBoelsen, LauraLimited data from Asia are available on long-term effects of pneumococcal conjugate vaccine introduction on pneumococcal carriage. Here we assess the impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on nasopharyngeal pneumococcal carriage prevalence, density and antimicrobial resistance. Cross-sectional carriage surveys were conducted pre-PCV13 (2015) and post-PCV13 introduction (2017 and 2022). Pneumococci were detected and quantified by real-time PCR from nasopharyngeal swabs. DNA microarray was used for molecular serotyping and to infer genetic lineage (Global Pneumococcal Sequence Cluster). The study included 1461 infants (5-8 weeks old) and 1489 toddlers (12-23 months old) enrolled from family health clinics. We show a reduction in PCV13 serotype carriage (with non-PCV13 serotype replacement) and a reduction in the proportion of samples containing resistance genes in toddlers six years post-PCV13 introduction. We observed an increase in pneumococcal nasopharyngeal density. Serotype 15 A, the most prevalent non-vaccine-serotype in 2022, was comprised predominantly of GPSC904;9. Reductions in PCV13 serotype carriage will likely result in pneumococcal disease reduction. It is important for ongoing surveillance to monitor serotype changes to potentially inform new vaccine development.Scopus© Citations 10
